Palisade Bio (PALI) Net Cash Flow (2010 - 2026)
Palisade Bio (PALI) posted quarterly Net Cash Flow of -$757000.0 for Q1 2026, up 70.78% year-over-year from -$443251.3 in Q1 2025, and down 100.59% quarter-over-quarter from $128.2 million in Q4 2025.
Powered by 
Analysis
Palisade Bio (PALI) Net Cash Flow (2010 - 2026) Analysis & Trends
Palisade Bio (PALI) has reported Net Cash Flow for 17 consecutive years, with -$757000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow rose 70.78% year-over-year to -$757000.0; the TTM figure through Mar 2026 stood at $125.4 million (up 3200.02% YoY), while the FY2025 annual figure was $123.6 million, up 4833.55% from the prior year.
- Net Cash Flow fell to -$757000.0 in Q1 2026 per PALI's latest filing, from $128.2 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $128.2 million in Q4 2025 and bottomed at -$3.9 million in Q1 2022.
- Historically, Net Cash Flow has averaged $7.2 million across 5 years, with a median of -$1.1 million in 2023.
- Annual changes were most pronounced in 2022 — Net Cash Flow slumped 3829.59% — and 2025, when it soared 7097.47%.
- Palisade Bio's Net Cash Flow stood at -$1.6 million in 2022, then tumbled by 79.78% to -$2.9 million in 2023, then surged by 161.84% to $1.8 million in 2024, then jumped by 7097.47% to $128.2 million in 2025, then sank by 100.59% to -$757000.0 in 2026.
- Business Quant data shows PALI's Net Cash Flow at -$757000.0 in Q1 2026, $128.2 million in Q4 2025, and -$190000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -183.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 374.50 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 407.41 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -496,000.00 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 225.59 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Palisade Bio | 440.73 Mn | 315.53 Mn | - | -7.46 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -7.46 Mn |
| Mar 31, 2026 | -757,000.00 |
| Dec 31, 2025 | 128.19 Mn |
| Sep 30, 2025 | -190,000.00 |
| Jun 30, 2025 | -1.81 Mn |
| Mar 31, 2025 | -2.59 Mn |
| Dec 31, 2024 | 1.78 Mn |
| Sep 30, 2024 | -3.31 Mn |
| Jun 30, 2024 | 77,000.00 |
| Mar 31, 2024 | -1.16 Mn |
| Dec 31, 2023 | -2.88 Mn |
| Sep 30, 2023 | -1.09 Mn |
| Jun 30, 2023 | 3.11 Mn |
| Mar 31, 2023 | 914,000.00 |
| Dec 31, 2022 | -1.60 Mn |
| Sep 30, 2022 | 9.01 Mn |
| Jun 30, 2022 | -1.66 Mn |
| Mar 31, 2022 | -3.85 Mn |
| Dec 31, 2021 | -3.61 Mn |
| Sep 30, 2021 | 1.45 Mn |